Check for updates

#### **OPEN ACCESS**

EDITED BY Ke Ren, University of Maryland, United States

REVIEWED BY Junya Sakamoto, Nagasaki University, Japan Mati Pääsuke, University of Tartu, Estonia

\*CORRESPONDENCE Maja R. Radojčić 🖾 maja.radojcic@manchester.ac.uk

RECEIVED 31 March 2023 ACCEPTED 07 August 2023 PUBLISHED 01 September 2023

#### CITATION

Radojčić MR, Perera RS, Hart DJ, Spector TD and Arden NK (2023) Prevalence, incidence, and re-occurrence risk of musculoskeletal pain in older adults in the United Kingdom: a population-based study. Front. Pain Res. 4:1197810. doi: 10.3389/fpain.2023.1197810

#### COPYRIGHT

© 2023 Radojčić, Perera, Hart, Spector and Arden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Prevalence, incidence, and re-occurrence risk of musculoskeletal pain in older adults in the United Kingdom: a population-based study

Maja R. Radojčić<sup>1,2\*</sup>, Romain S. Perera<sup>1,3,4</sup>, Deborah J. Hart<sup>5</sup>, Tim D. Spector<sup>5</sup> and Nigel K. Arden<sup>1,6</sup>

<sup>1</sup>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, <sup>2</sup>Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, <sup>3</sup>Department of Allied Health Sciences, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka, <sup>4</sup>Sports and Exercise Medicine Unit, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka, <sup>5</sup>Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom, <sup>6</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

**Background:** Throughout the literature, pain burden has been assessed by asking different questions, often cross-sectionally, different populations of interest. We know little about pain re-occurrence and how to translate knowledge between pain questions within the population of interest. We aimed to estimate the burden of musculoskeletal pain by estimating prevalence, incidence rates, and re-occurrence risk of back, hand, hip, knee, and foot pain using different questions from UK population-based samples and predict the number of affected individuals in the UK in 2030.

**Methods:** We used two UK population-representative studies, with two eightyear-apart follow-ups and two pain questions assessing recent pain episodes and often troubled pain when walking. We estimated prevalence, 8-year incidence rates, and 8-year pain re-occurrence risk for women and men aged 50 years and older and the relation between the two pain questions.

Results: Among UK individuals older than 50 years, the prevalence of musculoskeletal pain episode was 20%-50%, and the incidence was 20-40/1,000 person-years, while the prevalence of pain when walking was 10%-25%, and the incidence was 6-12/1,000 person-years. The most prevalent musculoskeletal pain types were back and knee pain; of five women experiencing back or knee pain episodes, three are expected to be often troubled by pain. Hip and foot pain had similar estimates in both questions. Hand pain peaked in women aged 50-65 years. Women had higher prevalence and incidence rates, but men had higher 8-year re-occurrence risk of all types of musculoskeletal pain. Reporting a pain episode was associated with two times higher risk, but often troubled by pain when walking was associated with four to seven times times higher risk of the same pain in 8 years. Women and men with a body mass index (BMI) of  $\geq$ 27 kg/m<sup>2</sup> were twice as likely to experience musculoskeletal pain than those with BMI<27 kg/m<sup>2</sup>. In 2030, we expect 2-7 million people older than 50 years in the United Kingdom to seek site-specific musculoskeletal pain-focused healthcare.

**Conclusions:** In individuals older than 50 years, the experience of musculoskeletal pain at least doubles the chance of experiencing it again. Women report musculoskeletal pain more often, but men report more persistent pain. Musculoskeletal pain presents a significant burden to public health.

KEYWORDS

prevalence, incidence rate, relative risk, re-occurrence, musculoskeletal pain, body mass index

#### Introduction

Pain is "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" (1). It is also the symptom that brings patients to seek medical care and, in chronic form, a health condition classified in the newest International Classification of Diseases (2). A 3-month duration is a criterion for defining chronicity. Chronic pain is a debilitating condition that negatively affects multiple aspects of individuals' health and consequently attracts significant research attention (3, 4). In musculoskeletal disease, where early disease diagnosis and disease-modifying medications are lacking, pain is the primary patient complaint, the reason for visiting health professionals, and the treatment focus (5, 6). However, not every musculoskeletal pain is chronic. A pain episode can last several weeks, a month, or two, and not meet the chronicity criterion. Yet, these patients use healthcare: physician visits, diagnostic tests, pharmacological treatments, physiotherapy, or surgery. Besides pain presence, intensity, and chronicity, limited activities and reduced quality of life are important dimensions for understanding pain burden. Pain episodes can re-occur after some time, or the underlying disease can be manifested in flares, indicating a repeated need for pain-focused healthcare. Thus, having epidemiological estimates of pain episodes and a link between different questions that are used to assess pain properties is of great interest to public health (7).

Several reports provided prevalence estimates of musculoskeletal pain in specific occupational and general populations (4, 8, 9). A few UK reports also provided cross-sectional estimates based on different pain questions (10–12), but none of the musculoskeletal pain re-occurrence or incidence rates. The prevalence has been often reported per sex and age group, the recognised risk factors. However, the body mass index (BMI) is also a risk factor, but the estimates per BMI group are lacking (13–16).

Therefore, given the public health importance and knowledge gaps, we aimed to provide the prevalence, incidence, and risk of re-occurrence of musculoskeletal pain. We used two population-representative UK cohorts and two pain questions assessing pain episodes irrespective of the duration and often troubled by pain when walking as an essential determinant of quality of life (17). Also, we aimed to provide the national estimate for the near future—2030. Finally, we intended to provide estimates per sex, age, and BMI group, considering a recently proposed BMI cut-off for musculoskeletal pain (15).

## **Methods**

#### Study samples

We used data from two English prospective population-based cohorts—the Chingford 1,000 women study and the English Longitudinal Study of Ageing (ELSA). The Chingford study started in 1989 in Chingford (Northeast London, UK) (18, 19). All women aged 45–65 years who registered in a large general practice were invited to partake in a longitudinal study assessing common medical conditions, particularly musculoskeletal diseases, and ageing. Of contacted, 1,003 (78% response rate) women participated in the first visit (18). The women have been followed up for 22 years, with irregular follow-ups, more frequent in the first decade (5, 14, 15). The Chingford study has been a UK women representative sample (19).

The ELSA study started in 2002 when women and men aged 50 years and older who participated in the Health Survey for England 1998/1999/2001 were invited for a longitudinal study focused on ageing (20). The study follow-ups (waves) were biannual interviews, with nurse visits every other wave starting from Wave 2, for clinical assessments such as body weight and height (13, 21). The study allowed the change in the interviewed household member over time, and new participants have been added over time. The ELSA study has been a UK household representative sample (21).

Here, we defined the study samples from the Chingford and the ELSA based on the following criteria: (1) available individual data on multi-site musculoskeletal pain on two assessments in longer term, i.e., closest to a decade apart and comparable between the studies, and (2) available data on age, sex, and body mass index. The data of interest were available approximately 8 years between the repeated assessments in both studies. Thus, we used the data from the follow-ups 1 and 8 from the Chingford and the Waves 2 and 6 from the ELSA performed in 1989, 1996, 2004, and 2012, respectively.

Of the 1,003 Chingford women who participated in the study in Year 1, 834 (83.2%) attended the Year 8 follow-up, had data on musculoskeletal pain and BMI, and made the Chingford study sample. The first nurse visit in the ELSA was at Wave 2 with 7,666 attending participants. Of these, 3,949 (51.5%) participated 8 years later at the Wave 6 nurse visit and had data on musculoskeletal pain and BMI. They formed the ELSA study sample (56% women). **Figure 1** shows the study flowchart.

Finally, we used the UK demographic data from the Office for National Statistics (ONS). These include the population of women and men aged 50 years and older in 4 calendar years of the



Chingford and ELSA assessments. Also, we used the ONS latest prediction (2020-based) for the UK population for 2030 (22).

The participants in both studies have provided their written informed consents for participation, and the relevant research ethics committees (for the Chingford: the Outer North East London Research Ethics Committee, and the ELSA: wave 2 - the London Multi-Centre Research Ethics Committee (MREC/04/2/ 006) and wave 6 - the NRES Committee South Central -Berkshire (11/SC/0374)) approved the studies.

#### Musculoskeletal pain

The musculoskeletal pain assessment in the Chingford study focused on episodes. In Year 1, women were asked about back, knee, and hand pain. The back pain question was whether they ever experienced episodes lasting more than a week, while knee and hand pain assessed the current pain in the left or right knee or any interphalangeal joint, left or right (15). In Year 8, women reported whether, in the last year, they experienced pain episodes in the back, knee, hand, hip, and foot (14). All variables were binary and, given slight differences in formulated questions, were interpreted as recent pain episodes that women could recall at the assessment.

The pain assessment in the ELSA focused on walking/mobility as a determinant of quality of life (17, 23). Firstly, the participants reported whether they are often troubled by pain, and when they positively answered, they rated pain in their back, knee, hip, and foot when walking on a flat surface on a scale of 0 (no pain) to 10 (severe pain) (21). From this scale, we created binary variables where zero meant no pain and any other value was the presence of pain in the specific part when walking (13).

#### Other measures

We used age, sex, and BMI for descriptive and stratification purposes (13, 15). All participants in the Chingford study were women. Their age was calculated as a difference between the assessment date and birth date, and their BMI from measured body weight and height (kg/m<sup>2</sup>) (15). The ELSA participants reported age and sex. During the nurse visit, the body weight and height were measured for BMI calculation (13). We created categorical age and BMI variables. Age categories were as follows: <50 (only in Chingford), 50-65, 65-80, and ≥80 years (only in ELSA). We used the BMI categories of the World Health Organization (WHO): underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5–25 kg/m<sup>2</sup>), overweight (25–30 kg/m<sup>2</sup>), and obese ( $\geq$ 30 kg/ m<sup>2</sup>). In addition, we used a recently proposed BMI cut-off for musculoskeletal pain. A study reported that over 19 years, women with BMI of 25-27 kg/m<sup>2</sup> had no different risk of musculoskeletal pain or mortality than women with BMI of  $<25 \text{ kg/m}^2$  (15). Therefore, we dichotomised BMI into the <27 and  $\geq$ 27 kg/m<sup>2</sup> groups.

#### Statistical analysis

We described the samples presenting means with standard deviation (SD) for continuous variables and frequencies (%) for categorical variables. We provided all sex-stratified estimates and visualised the prevalence of each pain type per age and BMI group. The prevalence of each musculoskeletal pain type was calculated as the number of cases that reported the pain by the total number of the included participants. We provided the pain prevalence at each assessment and both assessments. We computed the 8-year incidence rates by dividing the number of new cases at the second follow-up by the total number of person-years (expressed per 1,000 person-years). We provided 95% confidence intervals for the incidence rates using the Mid-P exact test implementing Miettinen's modification of the Fisher's test (24). We computed the re-occurrence risk as the ratio of the musculoskeletal pain risk/probability at the second follow-up (outcome) among those who reported the same pain type at the first assessment (exposed) to the outcome probability among those who did not report the pain at the first follow-up (nonexposed) (25).

Further, we used the observed data from the two UK cohorts and the ONS-provided UK population data to predict the number of affected individuals by each pain type on the population level and link estimates from two questions to the UK population in 2004, 2012, and 2030 years. To calculate the number of UK women with pain episodes in 2004 and 2012, we used the prevalence estimates from 1996 because there were more pain sites available. The prevalence estimates of pain when walking from 2004 to 2012 were recalculated to the year population estimates. Finally, we used ONS 2020-based predictions for the UK population in 2030 (22) and calculated the predicted number of individuals affected by each pain type using the

TABLE 1 Descriptive statistics of the study samples.

1996 and 2004 prevalence estimates. We also expressed these as the number of cases per 1,000 individuals.

We performed additional analyses exploring the proposed BMI cut-off for musculoskeletal pain (27 kg/m<sup>2</sup>). We provided prevalence per group. Further, we computed the prevalence ratio for each pain type as the ratio of the musculoskeletal pain risk/ probability (outcome) among those who had BMI of  $\geq$ 27 kg/m<sup>2</sup> (exposed) to the outcome probability among those who had BMI of <27 kg/m<sup>2</sup> (non-exposed) at the same assessment.

We used SPSS Statistics 27 (IBM, Chicago, IL, USA) and Microsoft Excel (version 16) for statistical analyses and graphic presentations.

#### Results

The descriptive statistics of the study samples are presented in **Table 1**. In Year 1, the Chingford women were, on average, 54 years old (SD = 5.9), with 29.6% younger than 50 years. They had an average BMI of 25.4 kg/m<sup>2</sup> (SD = 4.1), which increased to 26.7 kg/m<sup>2</sup> (SD = 4.7) in Year 8. In Wave 2, the participants of the ELSA were, on average, 64 years old (SD = 7.8), with 3.4% older than 80 years. Their average BMI was 27.9 kg/m<sup>2</sup> (SD = 4.7) and similar 8 years later, which was 28.2 kg/m<sup>2</sup> (SD = 5.1).

Back pain was the most prevalent type considering either question, followed by knee pain (Table 2). The 8-year re-occurrence risk of back pain episodes was 1.80 (95% CI 1.58–2.02), and of often troubled pain when walking was 4.23 (95% CI 4.09–4.38) for women and 5.34 (95% CI 5.14–5.55) for men. We found that in 2030 in the United Kingdom, we can expect 5.8 million women affected by back pain episodes, and 3.4 million women and 2 million men often troubled by activity-limiting back pain. Thus, out of five women experiencing a back pain episode,

Variable/study assessment (year)	The Chingford study N = 834		The ELSA study N = 3,949						
	Women	Women	All	Women (56%)	Men (44%)	All	Women (56%)	Men (44%)	
Age (years), mean (SD)	54.4 (5.9)	61.2 (5.9)	63.7 (7.8)	63.8 (7.9)	63.5 (7.7)	71.4 (7.7)	71.5 (7.8)	71.2 (7.6)	
Age groups (years), %									
<50	29.6	_	_	_	_	_	_	_	
50-65	70.4	70.1	57.9	57.4	58.5	22.4	22.3	22.6	
65-80	_	29.9	38.7	39.0	38.5	60.4	60.1	60.7	
≥80	_	_	3.4	3.7	3.1	17.2	17.6	16.8	
Body mass index, mean (SD)	25.4 (4.1)	26.7 (4.7)	27.9 (4.7)	28.0 (5.1)	27.8 (4.1)	28.2 (5.1)	28.3 (5.5)	28.1 (4.4)	
Body mass index groups (kg/m <sup>2</sup> ), %									
<18.5	0.7	1.0	0.6	0.7	0.4	0.9	1.2	0.5	
18.5-25.0	52.0	38.6	26.5	29.5	22.8	26.5	29.2	23.1	
25.0-30.0	34.7	39.6	44.9	39.5	51.8	41.9	36.4	48.9	
≥30.0	12.6	20.9	28.0	30.4	25.1	30.7	33.2	27.5	
<27	71.8	58.8	47.3	48.4	45.9	44.7	45.5	43.7	
≥27	28.2	41.2	52.7	51.6	54.1	55.3	54.5	56.3	

TABLE 2 Musculoskeletal pain in individuals aged 50	) years and older in the United Kingdom.
---	--

	Sample estimates					Predicted UK population estimates				
Pain variable	Prevalence, N (%)			Re-occurrence risk ratio (95% Cl) <sup>a</sup>	Incidence rate/1,000 person-years (95% CI) <sup>b</sup>	Prevalence, N <sup>c</sup>		Prevalence, <i>N</i> /1,000 <sup>d</sup>		
Pain episode <sup>e</sup>	1989	1996	Both years			2004	2012	2030	2030	
Back pain										
Women	308 (52.5)	233 (39.7)	155 (26.4)	1.80 (1.58-2.02)	18.98 (15.11-23.56)	4,307,258	4,704,549	5,788,721	397	
Knee pain										
Women	189 (32.2)	240 (40.9)	115 (19.6)	1.94 (1.75–2.12)	30.42 (25.43-36.12)	4,436,661	4,845,887	5,962,631	409	
Hand pain										
Women	203 (34.6)	303 (51.6)	135 (23.0)	1.52 (1.37-1.67)	40.88 (35.04-47.43)	5,601,284	6,117,932	7,527,821	516	
Hip pain										
Women	_	156 (26.6)	_	_	_	2,883,830	3,149,827	3,875,710	266	
Foot pain										
Women	_	135 (23.0)	_	_	_	2,495,622	2,725,811	3,353,980	230	
Pain when walking	2004	2012	Both years			2004	2012	2030	2030	
Back pain										
Women	517 (23.4)	520 (23.5)	293 (13.2)	4.23 (4.09-4.38)	12.82 (11.23-14.57)	2,535,083	2,784,980	3,407,014	234	
Men	265 (15.3)	259 (14.9)	127 (7.3)	5.34 (5.14-5.55)	9.50 (7.98-11.23)	1,419,067	1,571,477	2,011,780	153	
Knee pain										
Women	504 (22.8)	473 (21.4)	269 (12.2)	4.47 (4.32-4.62)	11.52 (10.02-13.19)	2,471,338	2,533,261	3,321,344	228	
Men	285 (16.4)	251 (14.5)	128 (7.4)	5.30 (5.09-5.51)	8.86 (7.39-10.53)	1,526,166	1,522,938	2,163,613	164	
Hip pain										
Women	416 (18.8)	349 (15.8)	175 (7.9)	4.34 (4.16-4.53)	9.83 (8.45-11.37)	2,039,835	1,869,150	2,741,427	188	
Men	186 (10.7)	147 (8.5)	69 (4.0)	7.37 (7.08–7.66)	5.62 (4.47-6.97)	996,024	891,920	1,412,042	107	
Foot pain										
Women	380 (17.2)	288 (13.0)	141 (6.4)	4.63 (4.42-4.83)	8.30 (7.04-9.73)	1,863,311	1,542,450	2,504,188	172	
Men	164 (9.4)	147 (8.5)	58 (3.3)	6.25 (5.96-6.54)	6.41 (5.18-7.85)	878,215	891,920	1,245,026	94	

<sup>a</sup>The re-occurrence risk ratio presents the ratio of the pain risk/probability at the second follow-up among those who reported the same pain type at the first assessment to the outcome probability among those who did not report the pain at the first follow-up.

<sup>b</sup>The incidence rate is the number of new cases at the second follow-up by the total number of person-years, expressed per 1,000 person-years.

<sup>c</sup>The predicted UK population estimates were obtained using 1996 pain episode, and 2004 and 2012 pain when walking estimates and applied to 2004, 2012, and 2030 UK population. According to the ONS, there were 9,967,191 women older than 50 years in 1989 and 10,139,958 in 1996 in the United Kingdom. In the same age group, there were 10,851,333 women and 9,296,226 men in 2004, and 11,852,232 women and 10,533,146 men in 2012. The 2020-based estimates for the UK 2030 population indicate that there will be 14,583,601 women and 13,179,059 men older than 50 years.

<sup>4</sup>The prevalence of musculoskeletal pain in 2030 in the United Kingdom presented as number (rounded to an integer) of cases per 1,000 individuals.

<sup>e</sup>In the Chingford study, the presented estimates of pain episodes were based on 587 women aged 50 years and older. There were no reports on hip and foot pain in 1989.

three are expected to be often troubled by back pain. We found very similar estimates for knee pain. Hand pain episodes had the highest incidence rate. The prevalence of hip and foot pain when walking was lower than the same type of knee pain, and the highest reoccurrence risk of musculoskeletal pain had men troubled by hip and foot pain. In 2030, we expect that out of four women experiencing a hip pain episode, three will be often troubled by hip pain, and out of five women reporting a foot pain episode, four women will be often troubled by it.

Figure 2 shows the prevalence of musculoskeletal pain per age and BMI group. We did not find a consistent age trend among older adults. Interestingly, hand pain episodes almost doubled in 50–65-year-old women compared with younger than 50 years. However, we did observe that the prevalence of musculoskeletal pain increased with higher BMI. Further, we found that using a BMI cut-off of 27 kg/m<sup>2</sup> (Table 3), the prevalence risk ratio of knee pain among women who had BMI of  $\geq$ 27 kg/m<sup>2</sup> was from 1.49 (95% CI 1.29–1.70) for pain episodes to 2.49 (95% CI 2.31– 2.67) higher for pain when walking than among women with BMI of  $\langle 27 \text{ kg/m}^2$ .

# Discussion

We found that musculoskeletal pain was prevalent among UK individuals aged 50 years and older, and back and knee pain were the most prevalent. Prevalence and incidence rates were higher in women than men. However, men had higher 8-year reoccurrence risks of all musculoskeletal pain types than women, indicating their tendency to report more persistent pain. The experience of musculoskeletal pain episodes was associated with an approximately two times higher risk but being often troubled by pain when walking indicated four to seven times higher risk of the same pain in 8 years. We did not observe prevalence trends per age group, except for hand pain that peaked in 50–65-year-old women. Yet, we found an increasing trend per BMI



group and supportive results for the BMI of 27 kg/m<sup>2</sup> cut-off in musculoskeletal research. In 2030, we expect 2–7 million people aged 50 years and older in the United Kingdom to seek site-specific musculoskeletal pain-focused healthcare.

Our study used high-quality UK population-representative cohorts, included five musculoskeletal sites, first time provided the incidence and re-occurrence risk, considered sex, ageing, and obesity impacts, and predicted national estimates for 2030. However, we acknowledge several limitations. Firstly, the 8-year participation of the same individuals in the ELSA study was lower than that in the Chingford study. At the first set of followups, we had a quarter of the Chingford women younger than 50 years and 3.4% of the ELSA participants older than 80 years. In longitudinal studies, the older participants tend to drop off earlier due to morbidity or mortality over time (15). In addition, the ELSA waves were not focused on following the same individuals, allowing different household members to be interviewed and including new participants over time. We showed the estimates per age group to minimise the differences, but estimates for the participants older than 80 years from the ELSA first follow-up are unlikely to be population-representative. Secondly, the pain episode estimates were unavailable for men because of the study design. Yet, we could compensate for that lack with the other cohort and report important sex differences. Also, the back pain episode estimates might not be the 8-year. The participants experiencing the condition of interest when asked are more likely to recall similar past events; however, we cannot rule out whether that back pain happened 2 or more years ago. Thirdly, we did not consider the underlying disease that caused the musculoskeletal pain. The most common disease is osteoarthritis (OA), and frequent troubled pain when walking is likely OA pain. The relationship between structural changes and pain is inconsistent, and we focused on the pain that the patients are concerned with the most and leads to healthcare expenditures (5, 26). Finally, we did not consider the effect of treatment that could affect pain reports. Our outcome was binary that minimises the misclassification. Pain severity would be affected by analgesics and orthopaedic procedures, but given that these treatments are not fully successful, the binary outcome should be the least affected by treatment effects (27).

Formulations of pain questions and study samples vary across studies influencing the estimates, comparisons, and interpretations. Studies using different questions in the same population are needed to help bridge and optimally interpret the evidence for public health and policy matter. The evidence is increasing that musculoskeletal pain is a huge burden, negatively affecting the ability to work and quality of life (4, 9, 28-33). The estimates in the older but still working population are essential because sick leave, reduced productivity, and early retirement contribute to socioeconomic burden (34). In the United Kingdom, the current state pension age is 66 years but enounced to increase to 68 years (35). We showed here that musculoskeletal pain is a considerable problem in UK individuals aged 50-65 years, i.e., before retirement. A US study assessed several types of musculoskeletal pain, and found, similarly to us, that the most prevalent in older adults were back and knee pain (4). We also showed that hip and foot pain were similarly prevalent, and the prevalence did not change much with the stringency of pain

	Pain episode								
	1989			1996					
	Prevalence		Prevalence ratio	Prevalence		Prevalence ratio			
	N (%)		(95% CI)	N (%)		(95% CI)			
	<27 kg/m <sup>2</sup>	$\geq$ 27 kg/m <sup>2</sup>		<27 kg/m <sup>2</sup>	$\geq$ 27 kg/m <sup>2</sup>				
Back pain									
Women	300 (50.1)	132 (56.2)	1.12 (0.98–1.26)	174 (35.5)	174 (35.5) 152 (44.2)				
Knee pain									
Women	162 (27.0)	95 (40.4)	1.49 (1.29–1.70)	160 (32.7)	168 (48.8)	1.50 (1.33-1.66)			
Hand pain									
Women	170 (28.4)	78 (33.2)	1.17 (0.95-1.39)	219 (44.7)	191 (55.5)	1.24 (1.11-1.38)			
Hip pain									
Women	-	-	_	106 (21.6)	103 (29.9)	1.38 (1.15–1.62)			
Foot pain									
Women	_	_	_	82 (16.7)	91 (26.5)	1.58 (1.32-1.85)			
	Pain when walking								
		2004		2012					
	Prevalence N (%)		Prevalence ratio	Prevalence		Prevalence ratio			
			(95% CI) <sup>a</sup>	N (%)		(95% CI) <sup>a</sup>			
	<27 kg/m <sup>2</sup>	≥27 kg/m <sup>2</sup>		<27 kg/m <sup>2</sup>	$\geq$ 27 kg/m <sup>2</sup>				
Back pain									
Women	191 (17.8)	326 (28.5)	1.60 (1.44–1.76)	176 (17.5)	344 (28.5)	1.89 (1.73–2.05)			
Men	85 (10.7)	180 (19.1)	1.79 (1.55–2.03)	94 (12.4)	165 (16.9)	1.36 (1.13–1.60)			
Knee pain									
Women	157 (14.7)	347 (30.4)	2.07 (1.90-2.24)	136 (13.5)	337 (28.0)	2.49 (2.31–2.67)			
Men	84 (10.6)	201 (21.4)	2.03 (1.79–2.26)	77 (10.2)	174 (17.8)	1.75 (1.50–2.00)			
Hip pain									
Women	148 (13.8)	268 (23.5)	1.70 (1.52–1.88)	114 (11.3)	235 (19.5)	1.90 (1.70–2.11)			
Men	62 (7.8)	124 (13.2)	1.69 (1.40–1.98)	46 (6.1)	101 (10.3)	1.70 (1.37–2.04)			
Foot pain									
Women	130 (12.1)	250 (21.9)	1.80 (1.61-2.00)	96 (9.5)	192 (15.9)	1.80 (1.57–2.03)			
Men	53 (6.7)	111 (11.8)	1.77 (1.46-2.09)	45 (5.9)	102 (10.4)	1.76 (1.42-2.09)			

TABLE 3 Musculoskeletal pain prevalence and prevalence ratio among individuals with a body mass index above 27 kg/m<sup>2</sup>.

<sup>a</sup>The prevalence (risk) ratio presents the ratio of the pain risk/probability among those who had a body mass index of  $\geq$ 27 kg/m<sup>2</sup> to the pain probability among those who had a body mass index of <27 kg/m<sup>2</sup> at the same assessment.

questions, indicating that hip and foot pain might manifest in more severe forms. It is of clinical and public health importance highlighting the need for carefully choosing treatments and considering that these patients will require a longer or repeated use of pain-focused healthcare. Interestingly, the hand pain prevalence is rarely reported, and two studies reported estimates similar with ours from 1989, but significantly lower than ours from 1996 (4, 10). Importantly, we observed that in women, hand pain episodes doubled in age 50–65 years compared with the age below 50 years and remained similar in age 65–80 years.

For the first time, we provided musculoskeletal pain incidence and re-occurrence risk using two questions and two cohorts from the same population. In our cohorts, the data collection was done in the late 1990s and the early 2000s. Although the prevalence changes, it is essential to have the estimates over different periods from high-quality studies to be able to observe the change, design public health interventions, and assess the effects of these interventions. We used different pain questions and aimed to provide a nexus between them. As expected, we found that a looser definition such as "any pain episode" resulted in higher prevalence and incidence and lower 8-year re-occurrence than a definition closer to chronic pain focused on quality of life instead of duration. The re-occurrence risk accounts for re-occurrence and persistent conditions. Importantly, we found that men had a higher re-occurrence risk of all musculoskeletal pain types than women. Thus, men reported pain less often, but in a more persistent/severe form.

Further, we observed increasing prevalence trends per BMI group in older adults. Therefore, future changes in musculoskeletal pain prevalence and incidence could change because of population lifestyle and health programs targeting obesity. The predicted 2030 estimates considered sex and age increase but not BMI, so if obesity increases/decreases, our prediction will underestimate/overestimate the reality. Notably, the average 8-year BMI difference in the United Kingdom was larger in the late 1990s (Chingford) than early 2000s (ELSA). Compliance with and attrition from weight management programs in older individuals is challenging, and engagement alternatives are needed. In a 19-year follow-up study, musculoskeletal pain and obesity were bidirectionally related and should be considered together in public policies (15). Also, a BMI of 25–27 kg/m<sup>2</sup> was not associated with pain or mortality (15). Therefore, advising older patients with musculoskeletal pain to attain a BMI of <27 kg/m<sup>2</sup> could be an alternative, relaxed goal. It could reduce the long-term risk of musculoskeletal pain while at the same time keeping other health risks low (15). Here, we confirmed that women and men with BMI of  $\geq$ 27 kg/m<sup>2</sup> were almost twice more likely to experience any musculoskeletal pain than those with BMI <27 kg/m<sup>2</sup>.

# Conclusions

Musculoskeletal pain was highly prevalent in UK populationrepresentative cohorts, thus, presenting a significant healthcare problem. Women had higher prevalence and incidence of musculoskeletal pain than men, but men reported more persistent pain. Back and knee pain were the most common, and the prevalence varied on the stringency of pain questions. Hip and foot pain were less reported, but different questions did not significantly change the prevalence. Hand pain peaked in women aged 50–65 years. As the population ages, more individuals will seek painfocused healthcare, but future changes in the prevalence and incidence are likely to change with BMI. For older adults, a BMI of 27 kg/m<sup>2</sup> should be further explored and considered as a relaxed goal for weight management, as it could reduce the musculoskeletal pain risk and, consequently, pain-focused healthcare expenditures.

## Data availability statement

The data analysed in this study are subject to the following licenses/restrictions: requests to access the Chingford 1000 Women Study data should be addressed to julie.damnjanovic@ ndorms.ox.ac.uk. All research proposals requesting data access will need specification of the analysis plan and approval of the scientific board before any data can be released. Data from the English Longitudinal Study of Ageing are available at the UK Data Service upon user registration.

## Ethics statement

The Chingford 1000 Women Study and the English Longitudinal Study of Ageing (ELSA) involving human participants were reviewed and approved by the Research Ethics Committees. The Outer North East London Research Ethics Committee approved the Chingford study. The ELSA Wave 2 received ethical approval from the London Multi-Centre Research Ethics Committee (MREC/04/2/006) and the ELSA Wave 6 from the NRES Committee South Central - Berkshire (11/SC/0374). The patients/participants provided their written informed consent to participate in this study.

# Author contributions

MRR: the conception and design of the study, analysis, interpretation of data, drafting the article, final approval of the version to be submitted, and responsibility for the integrity of the work as a whole. RSP: the conception and design of the study, interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. DJH: acquisition of data, interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. TDS: acquisition of data, interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. NKA: acquisition of data and funding, interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. All authors contributed to the article and approved the submitted version.

# Funding

The English Longitudinal Study of Ageing was developed by a team of researchers based at University College London, NatCen Social Research, the Institute for Fiscal Studies, the University of Manchester, and the University of East Anglia. The data were collected by NatCen Social Research. The English Longitudinal Study of Ageing is funded by the National Institute on Aging (Ref: R01AG017644) and by a consortium of UK government departments: Department for Health and Social Care; Department for Transport; Department for Work and Pensions, which is coordinated by the National Institute for Health Research (NIHR, Ref: 198-1074). Funding has also been provided by the Economic and Social Research Council (ESRC). The present study was supported by Versus Arthritis through Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis (grant number 21595). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### Acknowledgment

The authors would like to thank all the participants of the Chingford 1,000 Women Study and the English Longitudinal Study of Ageing (ELSA), Alan Hakim (The Wellington Hospital, the Chingford study coordinator), Maxine Daniels (Chingford Hospital, research nurse), and Alison Turner (University of Oxford, data manager) for their time and dedication to the Chingford study, research staff involved in the ELSA study design and data collection, as well as funding bodies for their support: Arthritis Research UK (now Versus Arthritis), the Oxford NIHR Musculoskeletal Biomedical Research Unit for funding contributions, National Institute on Aging in the US, and the National Institute for Health Research and the Economic and Social Research Council. The authors would also like to thank Julie Damnjanović (University of Oxford) for her valued support to the team and the study data management.

# **Conflict of interest**

TDS reported serving as a scientific consultant for Zoe Global Ltd. NKA reported receiving personal fees from Bristows LLP outside the submitted work.

## References

1. IASP. Terminology (2020). Available at: https://www.iasp-pain.org/resources/ terminology/ (Accessed 12 January 2022).

2. WHO. International classification of diseases 11th revision (2022). Available at: https://icd.who.int/en. (Accessed 12 January 2022)

3. Leveille SG, Fried L, Guralnik JM. Disabling symptoms: what do older women report? *J Gen Intern Med.* (2002) 17(10):766-73. doi: 10.1046/j.1525-1497.2002. 20229.x

4. Patel KV, Guralnik JM, Dansie EJ, Turk DC. Prevalence and impact of pain among older adults in the United States: findings from the 2011 national health and aging trends study. *Pain.* (2013) 154(12):2649–57. doi: 10.1016/j.pain. 2013.07.029

5. Chen L, Perera RS, Radojčić MR, Beckenkamp PR, Ferreira PH, Hart DJ, et al. Association of lumbar spine radiographic changes with severity of back pain-related disability among middle-aged, community-dwelling women. *JAMA Netw Open.* (2021) 4(5):e2110715. doi: 10.1001/jamanetworkopen.2021.10715

6. Radojčić MR, Arden NK, Yang X, Strauss VY, Birrell F, Cooper C, et al. Pain trajectory defines knee osteoarthritis subgroups: a prospective observational study. *Pain.* (2020) 161(12):2841–51. doi: 10.1097/j.pain.000000000001975

7. International Pain Summit of the International Association for the Study of Pain. Declaration of Montreal: declaration that access to pain management is a fundamental human right. *J Pain Palliat Care Pharmacother* (2011) 25(1):29–31. doi: 10.3109/15360288.2010.547560

8. Joseph L, Standen M, Paungmali A, Kuisma R, Sitilertpisan P, Pirunsan U. Prevalence of musculoskeletal pain among professional drivers: a systematic review. *J Occup Health.* (2020) 62(1):e12150. doi: 10.1002/1348-9585.12150

9. Halla-aho SM, Tilvis RS, Strandberg TE, Pitkala KH. Musculoskeletal pain and its treatment among older home-dwelling people: ten-year changes in two Finnish birth cohorts. *Arch Gerontol Geriatr.* (2013) 56(1):285–9. doi: 10.1016/j.archger. 2012.08.014

10. Peat G, Rathod-Mistry T, Paskins Z, Marshall M, Thomas MJ, Menz HB, et al. Relative prevalence and distribution of knee, hand and foot symptomatic osteoarthritis subtypes in an English population. *Musculoskeletal Care*. (2020) 18(2):219–24. doi: 10. 1002/msc.1457

11. Keenan AM, Drake C, Conaghan PG, Tennant A. The prevalence and impact of self-reported foot and ankle pain in the over 55 age group: a secondary data analysis from a large community sample. *J Foot Ankle Res.* (2019) 12:53. doi: 10.1186/s13047-019-0363-9

12. Williamson E, Sanchez Santos MT, Morris A, Garrett A, Conway O, Boniface G, et al. The prevalence of back and leg pain and the cross-sectional association with adverse health outcomes in community dwelling older adults in England. *Spine* (*Phila Pa 1976*). (2021) 46(1):54–61. doi: 10.1097/BRS.00000000003719

13. Perera RS, Chen L, Ferreira ML, Arden NK, Radojčić MR, Kluzek S. Age- and sex-specific effects of obesity, metabolic syndrome and its components on back pain: the English longitudinal study of ageing. *Joint Bone Spine*. (2022) 89 (5):105366. doi: 10.1016/j.jbspin.2022.105366

14. Perera RS, Chen L, Hart DJ, Spector TD, Arden NK, Ferreira ML, et al. Effects of body weight and fat mass on back pain—direct mechanical or indirect through inflammatory and metabolic parameters? *Semin Arthritis Rheum.* (2022) 52:151935. doi: 10.1016/j.semarthrit.2021.11.007.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

15. Radojčić MR, Perera RS, Chen L, Spector TD, Hart DJ, Ferreira ML, et al. Specific body mass index trajectories were related to musculoskeletal pain and mortality: 19-year follow-up cohort. *J Clin Epidemiol.* (2021) 141:54–63. doi: 10. 1016/j.jclinepi.2021.09.020.

16. Perera RS, Gulati M, Shah K, Hart DJ, Spector TD, Arden NK, et al. No evidence of leptin mediating the effect of body mass index on hand pain and its duration in the Chingford 1000 women study: original research supplementing the study by Gloersen et al. *Arthritis Rheumatol.* (2022) 74(8):1452-4. doi: 10.1002/art.42132

17. Syddall HE, Martin HJ, Harwood RH, Cooper C, Aihie Sayer A. The Sf-36: a simple, effective measure of mobility-disability for epidemiological studies. *J Nutr Health Aging*. (2009) 13(1):57–62. doi: 10.1007/s12603-009-0010-4

18. Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford study. *J Rheumatol.* (1993) 20(2):331–5.

19. Hart DJ, Spector TD. Cigarette smoking and risk of osteoarthritis in women in the general population: the Chingford study. *Ann Rheum Dis.* (1993) 52(2):93–6. doi: 10.1136/ard.52.2.93

20. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. (2013) 42(6):1640-8. doi: 10.1093/ije/dys168

21. Banks J, Batty GD, Breedvelt JJF, Coughlin K, Crawford R, Marmot M, et al. *English longitudinal study of ageing: waves 0–9, 1998–2019.* [data collection]. 38th Edition. UK Data Service. SN: 5050 (2021). doi: 10.5255/UKDA-SN-5050-25

22. ONS. Principal projection—UK population in age groups (2021). Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/ populationprojections/datasets/tablea21principalprojectionukpopulationinagegroups (Accessed 2 December 2021).

23. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of eq-5d (eq-5d-5L). *Qual Life Res.* (2011) 20(10):1727–36. doi: 10.1007/s11136-011-9903-x

24. Miettinen OS. Discussion of Conover's "some reasons for not using the yates continuity correction on 2 × 2 contingency tables". J Am Stat Assoc. (1974) 69:374–82.

25. Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. *Stat Med.* (2017) 36 (23):3760. doi: 10.1002/sim.7375

26. Guermazi A, Roemer FW, Felson DT, Brandt KD. Motion for debate: osteoarthritis clinical trials have not identified efficacious therapies because traditional imaging outcome measures are inadequate. *Arthritis Rheum.* (2013) 65 (11):2748–58. doi: 10.1002/art.38086

27. George SZ, Bolognesi MP, Bhavsar NA, Penrose CT, Horn ME. Chronic pain prevalence and factors associated with high impact chronic pain following total joint arthroplasty: an observational study. *J Pain.* (2022) 23(3):450–8. doi: 10.1016/j. jpain.2021.09.007

28. Cimas M, Ayala A, Sanz B, Agullo-Tomas MS, Escobar A, Forjaz MJ. Chronic musculoskeletal pain in European older adults: cross-national and gender differences. *Eur J Pain.* (2018) 22(2):333–45. doi: 10.1002/ejp.1123

29. Wang C, Pu R, Ghose B, Tang S. Chronic musculoskeletal pain, self-reported health and quality of life among older populations in South Africa and Uganda. *Int J Environ Res Public Health*. (2018) 15(12):2806. doi: 10.3390/ijerph15122806

30. Nasaif H, Alaradi M, Hammam R, Bucheeri M, Abdulla M, Abdulla H. Prevalence of self-reported musculoskeletal joint symptoms among nurses: a multicenter cross-sectional study in Bahrain. *Int J Occup Saf Ergon.* (2023) 29 (1):192–8. doi: 10.1080/10803548.2021.2025315

31. Souza Mattos de Araujo Vieira LM, de Oliveira Sato T. Prevalence of multisite pain and association with work ability—cross-sectional study. *Musculoskelet Sci Pract.* (2020) 50:102279. doi: 10.1016/j.msksp.2020.102279

32. Nakamura M, Nishiwaki Y, Ushida T, Toyama Y. Prevalence and characteristics of chronic musculoskeletal pain in Japan. *J Orthop Sci.* (2011) 16(4):424–32. doi: 10. 1007/s00776-011-0102-y

33. Thiem U, Lamsfuss R, Gunther S, Schumacher J, Baker C, Endres HG, et al. Prevalence of self-reported pain, joint complaints and knee or hip complaints in adults aged  $\geq$  40 years: a cross-sectional survey in Herne, Germany. *PLoS One.* (2013) 8(4):e60753. doi: 10.1371/journal.pone.0060753

34. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. *Nat Rev Rheumatol.* (2014) 10(7):437–41. doi: 10.1038/nrrheum. 2014.44

35. UK Government. Second state pension age review launches (2022). Available at: https://www.gov.uk/government/news/second-state-pension-age-review-launches (Accessed 24 January 2022).